Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (209 reviews)

For research use only.

Catalog No.S1011

209 publications

CAS No. 850140-72-6

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

Selleck's Afatinib (BIBW2992) has been cited by 209 publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cell Death Dis, 2020, 2;11(1):6

PubMed: 31919341 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )
Antimicrob Agents Chemother, 2020, 1;AAC.00341-20

PubMed: 32482675 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):847-856 eCollection 2020

PubMed: 32269717 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Korean J Parasitol, 2020, 58(3):249-255

PubMed: 32615738 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Genome Biol, 2020, 21(1):181

PubMed: 32727536 ( click the link to review the publication )

J Cancer, 2020, 11(1):241-250

PubMed: 31892990 ( click the link to review the publication )

Neurooncol Adv, 2020, Dec;2(1):vdaa020

PubMed: 32226941 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )
J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )
Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9):e8746

PubMed: 30021798 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )
Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )
Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )
Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )
Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )
Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	M1G0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PxfGlEPTB;MD6wNFU4OiEQvF2=	MUjTRW5ITVJ?
KASUMI-1	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjEZYVKSzVyPUCuNFA6OTFizszN	MUHTRW5ITVJ?
HCC2218	NUXZVIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFuwUZBKSzVyPUCuNFA6QDdizszN	NYLsd2x4W0GQR1XS
KARPAS-45	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HXSGlEPTB;MD6wNVY4OSEQvF2=	MlzRV2FPT0WU
HSC-4	NEPCSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzaTItKSzVyPUCuNFE4PDhizszN	M2fiN3NCVkeHUh?=
CHL-1	NFq1d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofZTWM2OD1yLkCxPFM6KM7:TR?=	M1TvNXNCVkeHUh?=
KY821	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPNeFBxUUN3ME2wMlAzODZizszN	NUX3XZlzW0GQR1XS
NCI-N87	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMEK3O\|Mh\|ryP	NHv2bGdUSU6JRWK=
DOK	M3LhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmq2TWM2OD1yLkCzNVk1KM7:TR?=	NIDnRWpUSU6JRWK=
DSH1	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXFTWM2OD1yLkCzN\|E1KM7:TR?=	M1\JTXNCVkeHUh?=
MDA-MB-175-VII	NFv0eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEO0NVYh\|ryP	MYfTRW5ITVJ?
NCI-H2170	NYDZWWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn6WmU3UUN3ME2wMlA{PzJ6IN88US=>	NGizXVdUSU6JRWK=
BT-474	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMES5PFYh\|ryP	MV7TRW5ITVJ?
EFO-27	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMEWxPFIh\|ryP	MnzyV2FPT0WU
NCI-H720	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rDNWlEPTB;MD6wOVMzPSEQvF2=	MY\TRW5ITVJ?
PC-14	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjvZ4NKSzVyPUCuNFU3PjhizszN	NX3kTotkW0GQR1XS
EC-GI-10	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\ydop5UUN3ME2wMlA2QTF{IN88US=>	NFTpfolUSU6JRWK=
KYSE-450	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XlUWlEPTB;MD6wOVk4QCEQvF2=	MU\TRW5ITVJ?
BPH-1	NYm4OYt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LGeGlEPTB;MD6wOVk5QCEQvF2=	NGfBO4hUSU6JRWK=
NCI-H292	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfTTWM2OD1yLkC2NFkh\|ryP	M{flUnNCVkeHUh?=
H9	NVLzbnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XJZWlEPTB;MD6wO\|E{OiEQvF2=	NHXOXYxUSU6JRWK=
NCI-H526	M3y0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrXSFRCUUN3ME2wMlA4QDJ\|IN88US=>	M2W5NXNCVkeHUh?=
NCI-H1623	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\3T3RKSzVyPUCuNFgxOjVizszN	NW\mUopsW0GQR1XS
KYSE-140	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPzTWM2OD1yLkC4N\|Mh\|ryP	MmfUV2FPT0WU
Ca9-22	MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMEizOVMh\|ryP	NHrlWXRUSU6JRWK=
AU565	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{eyO2lEPTB;MD6wPFUxPCEQvF2=	NEHG[G9USU6JRWK=
ZR-75-30	NVnWRmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEm1OFUh\|ryP	MX3TRW5ITVJ?
NCI-H1770	NHnGSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMUCyPEDPxE1?	MlvOV2FPT0WU
LB2241-RCC	NXfqR\|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PLSGlEPTB;MD6xNFg5PCEQvF2=	MmLxV2FPT0WU
CAL-39	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13RWmlEPTB;MD6xNVc6OiEQvF2=	Mn:xV2FPT0WU
UACC-893	NUnPZXVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV25XWRqUUN3ME2wMlEyQDh3IN88US=>	NGLyUHVUSU6JRWK=
LU-65	M1rXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHraXINKSzVyPUCuNVI3OzNizszN	MojGV2FPT0WU
HN	NXj3OGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT5TWM2OD1yLkGzNFc4KM7:TR?=	M{D3R3NCVkeHUh?=
TI-73	NWP4VGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\2WGlEPTB;MD6xOFcyPSEQvF2=	MV3TRW5ITVJ?
KU812	MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPqTVU4UUN3ME2wMlE2PDV4IN88US=>	MoTCV2FPT0WU
SW13	M3npOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEf6[VFKSzVyPUCuNVYzOTZizszN	M{LYZ3NCVkeHUh?=
BB30-HNC	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HiS2lEPTB;MD6xOlU4PiEQvF2=	NWnsRYZMW0GQR1XS
HSC-2	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXjNZFKSzVyPUCuNVY5OzdizszN	M1:4cXNCVkeHUh?=
BV-173	Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT1UYNKSzVyPUCuNVc2QTZizszN	MV\TRW5ITVJ?
CAL-27	NGfPcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMUe2N\|Yh\|ryP	NEXYSopUSU6JRWK=
SBC-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DmSGlEPTB;MD6xPFk2QSEQvF2=	MWDTRW5ITVJ?
CAL-33	NHTib2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nEdWlEPTB;MD6yNFE5PCEQvF2=	M3y0Z3NCVkeHUh?=
NCI-H209	NGrseotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1j2WWlEPTB;MD6yNFQ3KM7:TR?=	MlOyV2FPT0WU
COR-L105	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMkGwPFQh\|ryP	MlrGV2FPT0WU
HSC-3	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMkGxPVgh\|ryP	Mn\nV2FPT0WU
NCI-H69	M{X1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXCZ\|FTUUN3ME2wMlIyPDVzIN88US=>	M3rvV3NCVkeHUh?=
MOLT-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;OTWM2OD1yLkKzPVc2KM7:TR?=	NFz0UZVUSU6JRWK=
ML-2	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jqfmlEPTB;MD6yOFgxOiEQvF2=	NFjCcWRUSU6JRWK=
IGROV-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMkW5OVIh\|ryP	NG\QWXJUSU6JRWK=
TK10	NYfEb2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXmUo5nUUN3ME2wMlI3PzN6IN88US=>	MY\TRW5ITVJ?
EoL-1-cell	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPuTWM2OD1yLkK2PFkzKM7:TR?=	NVnJ[nZbW0GQR1XS
HO-1-N-1	NHPkSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TyT2lEPTB;MD6yO\|g2OyEQvF2=	M1SwfnNCVkeHUh?=
BHY	M4Lyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\ITWM2OD1yLkK4OlU2KM7:TR?=	MnW3V2FPT0WU
LU-139	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi1OXJnUUN3ME2wMlMxPTFizszN	NIXsR\|dUSU6JRWK=
23132-87	NYq1Zox4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrGWoQyUUN3ME2wMlMyQTJ\|IN88US=>	MVHTRW5ITVJ?
ACHN	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwM{G5PVQh\|ryP	MmT6V2FPT0WU
DoTc2-4510	NFnCeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwM{KyNVkh\|ryP	MoT6V2FPT0WU
BB65-RCC	NInDc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXuzbIhGUUN3ME2wMlM1PTl\|IN88US=>	MYLTRW5ITVJ?
HLE	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f5c2lEPTB;MD6zOVA1PiEQvF2=	NFHWOHZUSU6JRWK=
HCC1419	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXnTWM2OD1yLkO2OFA5KM7:TR?=	MWrTRW5ITVJ?
A388	M3rK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;sW2lEPTB;MD6zOlg2PyEQvF2=	M4\4fnNCVkeHUh?=
NUGC-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrjWFlKSzVyPUCuN\|g{PzNizszN	NEn1[2RUSU6JRWK=
KYSE-180	NEn4V3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmL4TWM2OD1yLkO5NFg6KM7:TR?=	M4jJeHNCVkeHUh?=
TE-6	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNECyOFYh\|ryP	MVLTRW5ITVJ?
A498	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVO4WlZlUUN3ME2wMlQxPjd2IN88US=>	NUjaNJY3W0GQR1XS
NCI-H1648	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1G3UWlEPTB;MD60OFE5OiEQvF2=	M{LaXnNCVkeHUh?=
DU-145	M1HDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvoc4dwUUN3ME2wMlQ1QDN\|IN88US=>	MVfTRW5ITVJ?
CW-2	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PmOGlEPTB;MD60OlkyPCEQvF2=	NF3H[4FUSU6JRWK=
A431	M2PWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwNEiyN\|Mh\|ryP	MUHTRW5ITVJ?
SAS	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwNEizPVgh\|ryP	M2Ls[HNCVkeHUh?=
NCI-H2126	NWDZcHFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwNUG5NlYh\|ryP	M3vQVXNCVkeHUh?=
NCI-H358	MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIThNotKSzVyPUCuOVMzOSEQvF2=	Mnu5V2FPT0WU
FADU	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrRTXRKSzVyPUCuOVQ1ODRizszN	NGHIXIRUSU6JRWK=
ACN	NXnHb4poT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXLb5ZKSzVyPUCuOVUxQTRizszN	NGPzUlBUSU6JRWK=
HCC70	M3nJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL1c4NpUUN3ME2wMlU4PjZzIN88US=>	MWPTRW5ITVJ?
NCI-H1838	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwNkCyPVkh\|ryP	MoSzV2FPT0WU
CAL-54	NGLDOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwNkG2NlEh\|ryP	NGHjbZFUSU6JRWK=
NCI-H1975	NUDyTmx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\JTWM2OD1yLk[xO\|I5KM7:TR?=	M{jCWXNCVkeHUh?=
COR-L88	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37KNmlEPTB;MD62OFEyOyEQvF2=	NYrteWY6W0GQR1XS
CTV-1	NWrwb5ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTOeXZ5UUN3ME2wMlY1Ozl{IN88US=>	NWDve\|RSW0GQR1XS
EW-18	NGLIOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXLTWM2OD1yLk[4Olk5KM7:TR?=	MYTTRW5ITVJ?
HCC1806	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXXZYw2UUN3ME2wMlY6PjZ4IN88US=>	MmPGV2FPT0WU
HuP-T4	NHfPVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfBUZpKSzVyPUCuOlk4PiEQvF2=	M{fBRXNCVkeHUh?=
MDA-MB-361	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGH0S3VKSzVyPUCuO\|I3PjJizszN	MVLTRW5ITVJ?
NCI-H1573	NED0[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwN{O2N{DPxE1?	MkGxV2FPT0WU
KU-19-19	NV3HNoVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwN{e0OlQh\|ryP	NVq4XohWW0GQR1XS
COLO-678	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnT1TWM2OD1yLkiwPFM1KM7:TR?=	Mn\LV2FPT0WU
C-33-A	M3f1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIi5XGhKSzVyPUCuPFEzQTdizszN	M3zYR3NCVkeHUh?=
Calu-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwOEG0N\|Qh\|ryP	MkH3V2FPT0WU
AGS	NG\mWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrtW21HUUN3ME2wMlg{PjR6IN88US=>	MVfTRW5ITVJ?
SCC-25	NHvveIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwOESxO\|Eh\|ryP	NXO5OZh{W0GQR1XS
JVM-2	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnEW41KSzVyPUCuPFgzQTlizszN	NWnBclU{W0GQR1XS
HCE-T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Xt[GlEPTB;MD64PFQzQCEQvF2=	NV;wOFViW0GQR1XS
ES4	NHPWOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLnTWM2OD1yLkm3PFM3KM7:TR?=	NHrVd4FUSU6JRWK=
EKVX	NIHmb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf2TWM2OD1zLkCxNFY1KM7:TR?=	M1fOenNCVkeHUh?=
D-542MG	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorWTWM2OD1zLkCxNFY1KM7:TR?=	M1L2cHNCVkeHUh?=
SW1116	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzuTWM2OD1zLkCxNlg4KM7:TR?=	NF64d3RUSU6JRWK=
5637	NELiWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLVfmtWUUN3ME2xMlAyPTFizszN	M1vxdHNCVkeHUh?=
HT-1376	M2KzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTFwMEG1NVMh\|ryP	Mn3KV2FPT0WU
NB69	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPLfph4UUN3ME2xMlAzQTR3IN88US=>	MWnTRW5ITVJ?
YKG-1	MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPhS25KSzVyPUGuNFU1OTlizszN	MlvCV2FPT0WU
EW-3	M4\ISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfGSoFiUUN3ME2xMlA4QDh\|IN88US=>	MV\TRW5ITVJ?
GCIY	NGDUPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XN[2lEPTB;MT6wPFExPCEQvF2=	Ml7uV2FPT0WU
SK-MES-1	NEfBVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFwMUG0PFch\|ryP	NXfwZnB1W0GQR1XS
PANC-08-13	M{Tpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPhTWM2OD1zLkG2OFE3KM7:TR?=	NW\k[\|dXW0GQR1XS
SK-NEP-1	NWjSOmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXmwNnFZUUN3ME2xMlE4PTF\|IN88US=>	Mn3wV2FPT0WU
SW954	NH7hd\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\lO2lEPTB;MT6yNFIyPCEQvF2=	NYX4fGpRW0GQR1XS
NCI-SNU-5	NHLRSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PKVGlEPTB;MT6yN\|kh\|ryP	NXTzT3p{W0GQR1XS
SW48	NFPPUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3POXmlEPTB;MT6yOVQ{OiEQvF2=	MV;TRW5ITVJ?
HT-3	NHHuNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFwMki3OVMh\|ryP	MkHaV2FPT0WU
ETK-1	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7GcYdKSzVyPUGuN\|c1PTZizszN	M2LpU3NCVkeHUh?=
SCC-15	M4\R[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm5bGFKSzVyPUGuN\|k1PTFizszN	M3HRXnNCVkeHUh?=
DU-4475	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LxbGlEPTB;MT60NFEzOSEQvF2=	M1XUeHNCVkeHUh?=
NB5	NX7kcotmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{O2fWlEPTB;MT60NVMyPyEQvF2=	MnTzV2FPT0WU
CFPAC-1	NUDlXVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;KR2lEPTB;MT60NlQ6OyEQvF2=	M4jpTHNCVkeHUh?=
NCI-H630	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3h[FBKSzVyPUGuOFU2QDJizszN	NEjKR5hUSU6JRWK=
NCI-H82	M1G1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFwNUSwNFYh\|ryP	MULTRW5ITVJ?
ECC10	NVHrXVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLxV4lKSzVyPUGuOVU{PjlizszN	M3WwcXNCVkeHUh?=
K5	M1nt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13Pe2lEPTB;MT61PFM2PyEQvF2=	NFnmOnRUSU6JRWK=
ME-180	NULHfFQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTFwNkGwPVYh\|ryP	NHz1NG1USU6JRWK=
KYSE-410	M4ewb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTFwNkW2O\|Ih\|ryP	MkHWV2FPT0WU
G-401	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXzTWM2OD1zLk[3OFE{KM7:TR?=	MnTIV2FPT0WU
TGBC24TKB	NVTPd3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrnTWM2OD1zLk[4NlMh\|ryP	M4XGdXNCVkeHUh?=
Detroit562	M3fZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ri[GlEPTB;MT63NFE2OiEQvF2=	NWnw[W5xW0GQR1XS
OE19	NWrvNGhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfOTWM2OD1zLkexOVEzKM7:TR?=	MWHTRW5ITVJ?
CAKI-1	NF3rbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rB[GlEPTB;MT63PFIyOSEQvF2=	MV7TRW5ITVJ?
TE-12	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGq5VVVKSzVyPUGuPFA1OTRizszN	NIezbYFUSU6JRWK=
NCI-H1666	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTFwOEC5OFgh\|ryP	NVriW\|ZDW0GQR1XS
TE-1	NYHE[WUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1i3cmlEPTB;MT64NVQ4PSEQvF2=	M3HQRnNCVkeHUh?=
CAL-12T	M{S4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTFwOEi5OFUh\|ryP	NFXMN4hUSU6JRWK=
TE-8	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvkZZhKSzVyPUGuPVE{PzdizszN	MXzTRW5ITVJ?
KYSE-270	NHnJTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[yTWM2OD1{LkCyO\|MzKM7:TR?=	NYPaVmxnW0GQR1XS
GMS-10	NIHvW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkezTWM2OD1{LkCzOVE4KM7:TR?=	NFrVV5BUSU6JRWK=
A2780	M3vjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13SNWlEPTB;Mj6wOlI6PCEQvF2=	NFjJU25USU6JRWK=
OMC-1	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfBeoRYUUN3ME2yMlA5OTZ7IN88US=>	MXPTRW5ITVJ?
LoVo	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\BTWM2OD1{LkGwO\|k4KM7:TR?=	MUXTRW5ITVJ?
PANC-03-27	NHXTO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;vS3c6UUN3ME2yMlE3PjNzIN88US=>	M1zMW3NCVkeHUh?=
MDA-MB-157	M3PYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTJwMkG4Nlgh\|ryP	M3fv[HNCVkeHUh?=
CaR-1	NEjzR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTJwMkiyPFEh\|ryP	MoDJV2FPT0WU
769-P	NHPkOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPNTWM2OD1{LkK5NFM4KM7:TR?=	MUnTRW5ITVJ?
NB7	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\R[FdHUUN3ME2yMlI6Pjd4IN88US=>	NFWye4NUSU6JRWK=
MKN7	M1yyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTJwM{WzN\|Uh\|ryP	NYTUZm5NW0GQR1XS
NCI-H1048	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXpPJhKSzVyPUKuOFkyPThizszN	M1vENXNCVkeHUh?=
RCM-1	NU[zfXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTJwNUK5N\|gh\|ryP	NHq0RoRUSU6JRWK=
HT55	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULNc\|RvUUN3ME2yMlU4OzhizszN	NVm2d5I5W0GQR1XS
HCC1569	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJwNUiyPVch\|ryP	NInGdnFUSU6JRWK=
LXF-289	M4XRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\ETWM2OD1{Lk[zOVY2KM7:TR?=	NXXpOI9mW0GQR1XS
OVCAR-3	M{jrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P4UmlEPTB;Mj62O\|E3PyEQvF2=	MmLXV2FPT0WU
TE-10	M{HXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:2[\|dFUUN3ME2yMlY5ODd6IN88US=>	MYPTRW5ITVJ?
SNU-C2B	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUCweJhqUUN3ME2yMlY5PjF4IN88US=>	MVLTRW5ITVJ?
LB1047-RCC	M1GzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTNTZlKSzVyPUKuO\|Q5QDhizszN	MWTTRW5ITVJ?
SN12C	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjqfoZoUUN3ME2yMlkyQTZ2IN88US=>	NVfMPWlwW0GQR1XS
786-0	NXvxcnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHeyU\|ZKSzVyPUOuNFY1ODhizszN	NH7TTGpUSU6JRWK=
HT-29	NWWw[mtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjUUY9ZUUN3ME2zMlA4OzB7IN88US=>	NFWyU3RUSU6JRWK=
RPMI-7951	M4HwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjRVXI6UUN3ME2zMlA4PTlizszN	NIXFblFUSU6JRWK=
NBsusSR	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\XTWM2OD1\|LkG4NlU1KM7:TR?=	NI[ySHlUSU6JRWK=
NKM-1	M3rx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXraZmVEUUN3ME2zMlE5PzR2IN88US=>	NGLieYdUSU6JRWK=
Capan-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHCTWM2OD1\|LkS2PFc2KM7:TR?=	NGjwRZNUSU6JRWK=
MKN1	NUHhTId4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nLUGlEPTB;Mz60O\|ExQCEQvF2=	M17EcnNCVkeHUh?=
OAW-42	NIPE[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4L2SmlEPTB;Mz61NFAzPiEQvF2=	Mlj2V2FPT0WU
SKG-IIIa	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjUSYc3UUN3ME2zMlUzOjN5IN88US=>	M2rHe3NCVkeHUh?=
no-11	M1Sxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTNwNUO1OlQh\|ryP	M4\KS3NCVkeHUh?=
NY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHWTWM2OD1\|LkWzOlU2KM7:TR?=	NFO1R\|hUSU6JRWK=
HEC-1	NYPoRVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrjbGxqUUN3ME2zMlU5QTVizszN	M{fyUXNCVkeHUh?=
NCI-H441	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknlTWM2OD1\|LkW5PFQyKM7:TR?=	M2XOVXNCVkeHUh?=
NCI-H2009	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrXTWM2OD1\|Lk[xNlE3KM7:TR?=	MoPUV2FPT0WU
T47D	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInsRmNKSzVyPUOuOlIzOTdizszN	M3nxTHNCVkeHUh?=
SNU-449	NVG3bItUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTNwNkW4NlYh\|ryP	MV;TRW5ITVJ?
NCI-SNU-1	NInUXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7YTWM2OD1\|Lk[5O\|M2KM7:TR?=	MkjvV2FPT0WU
BT-20	NIW0emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrGOoxKSzVyPUOuOlk4QTVizszN	M1;yUXNCVkeHUh?=
LS-123	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLZTWM2OD1\|Lke0Nlg1KM7:TR?=	MUjTRW5ITVJ?
8305C	NEjtbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDy[mU6UUN3ME2zMlc2QTFzIN88US=>	NUnxOpk6W0GQR1XS
OCUB-M	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTNwN{[xPFch\|ryP	NE[yenZUSU6JRWK=
KOSC-2	NVTFPXlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTNwOEO0OVEh\|ryP	MWPTRW5ITVJ?
NCI-H1693	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\nc4hxUUN3ME2zMlg1OThzIN88US=>	NEfYTGVUSU6JRWK=
TE-9	NIHaZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfIU4cyUUN3ME2zMlg1Ozh{IN88US=>	NHHZbppUSU6JRWK=
MV-4-11	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDCOVF2UUN3ME2zMlg4QTl2IN88US=>	NFTw[GlUSU6JRWK=
GAMG	NXPvb48{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3oN5dzUUN3ME2zMlkyOzF2IN88US=>	Mn3QV2FPT0WU
KNS-62	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTNwOUS3N\|Eh\|ryP	M3zpbnNCVkeHUh?=
MC116	NX;WW3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYGybIlVUUN3ME2zMlk2PDh7IN88US=>	NWP3PVBTW0GQR1XS
647-V	NX7LNZJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXuTWM2OD1\|Lkm4OFUzKM7:TR?=	Mk[5V2FPT0WU
U-87-MG	NH;EVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTRwMUC0PFEh\|ryP	MnvXV2FPT0WU
RPMI-8226	NF3uXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTRwMUG2N\|Eh\|ryP	NVT3O\|dOW0GQR1XS
SW1417	NY[4c4JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHkSXdjUUN3ME20MlEzOTR5IN88US=>	Mn\JV2FPT0WU
LAMA-84	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHPNGRKSzVyPUSuNVcxOiEQvF2=	NXz1UZhEW0GQR1XS
LS-513	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTRwM{GyNVch\|ryP	M4jLNXNCVkeHUh?=
KLE	NE\XZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPZXFU5UUN3ME20MlQxQDF7IN88US=>	NGPjO5NUSU6JRWK=
HCT-116	NV;rXHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\B[2lEPTB;ND60NVAxPyEQvF2=	MkP5V2FPT0WU
EPLC-272H	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTRwNEG1N\|Mh\|ryP	NVP5XIZpW0GQR1XS
KS-1	M175PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7JO\|FKSzVyPUSuOVA5QDlizszN	M2W4WHNCVkeHUh?=
HT-1197	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjwTWM2OD12LkWyOlY6KM7:TR?=	MnH1V2FPT0WU
LCLC-97TM1	NWiwbFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVS3OFhYUUN3ME20MlU{Pjh4IN88US=>	MlnBV2FPT0WU
ES5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTRwOEO3NlMh\|ryP	M1\5b3NCVkeHUh?=
CTB-1	NYrCVGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGP4eoFKSzVyPUSuPFQ5QCEQvF2=	NFzDSFRUSU6JRWK=
HL-60	NUHGenM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jaVGlEPTB;ND64OlYyOSEQvF2=	MnTEV2FPT0WU
VM-CUB-1	NInuTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PaVmlEPTB;ND64OlgyQSEQvF2=	NXz1fmNmW0GQR1XS
MEG-01	NXK5e\|JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlu1TWM2OD12Lkm5OFA{KM7:TR?=	NX7PboNVW0GQR1XS
KYSE-520	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO0TWM2OD13LkKwPFM6KM7:TR?=	NFWwTGFUSU6JRWK=
HuO-3N1	NVe3Z5o1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;rbW9PUUN3ME21MlI1ODR\|IN88US=>	NXrtTVdLW0GQR1XS
SW620	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTVwMkS5OlQh\|ryP	MV\TRW5ITVJ?
U031	NIHvTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LsfmlEPTB;NT6yOVQzPCEQvF2=	NHHLXm1USU6JRWK=
TE-5	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfhe41KSzVyPUWuOFA5PSEQvF2=	MWPTRW5ITVJ?
NCI-H747	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4V2lEPTB;NT60NlQ4OiEQvF2=	NX;sZodPW0GQR1XS
MG-63	NU\4bZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnPVlBPUUN3ME21MlQ5PzZ{IN88US=>	MnXRV2FPT0WU
HC-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH4W5BKSzVyPUWuOVE5OzlizszN	NETTVY1USU6JRWK=
HCC2998	NFPYNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j4WGlEPTB;NT61NlYyPSEQvF2=	MV7TRW5ITVJ?
NTERA-S-cl-D1	NHvNdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTVwNUS1N\|ch\|ryP	MlLIV2FPT0WU
KINGS-1	M12xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH0SoVKSzVyPUWuOlA6PDRizszN	MVnTRW5ITVJ?
D-423MG	M1PuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37sUGlEPTB;NT62NVcxPSEQvF2=	M1;6XXNCVkeHUh?=
SW962	M3TuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXlTnlKSzVyPUWuOlIxOzJizszN	NV;V[2k2W0GQR1XS
LOXIMVI	M1m3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTVwNkO4O\|Mh\|ryP	NIPmRWZUSU6JRWK=
LS-411N	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Kw[WlEPTB;NT63PVQ1OSEQvF2=	M{nxNXNCVkeHUh?=
NCI-H2291	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTVwOUi5OFMh\|ryP	MWrTRW5ITVJ?
A549	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml6yTWM2OD14LkGyOVU{KM7:TR?=	MlfJV2FPT0WU
LS-1034	NGTQRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm[0TWM2OD14LkKwO\|A3KM7:TR?=	NFrpUItUSU6JRWK=
NB14	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrCTWM2OD14LkSzPFM3KM7:TR?=	NXPrcG41W0GQR1XS
NCI-H1299	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTZwNkOxO\|Eh\|ryP	NE\ibG5USU6JRWK=
BT-549	NEXWfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jsTGlEPTB;Nj62Olg5QSEQvF2=	NF65VGNUSU6JRWK=
J-RT3-T3-5	NEHJeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HacmlEPTB;Nj64Olkh\|ryP	MkTwV2FPT0WU
SW756	NGn6TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTZwOUGxO\|Yh\|ryP	M4XKfHNCVkeHUh?=
DJM-1	NFLx[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTZwOUKwNVIh\|ryP	M4DTbXNCVkeHUh?=
GP5d	NWny[VQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjRfFlKSzVyPU[uPVc{QTRizszN	MnzqV2FPT0WU
MOLT-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXKV\|VKSzVyPUeuNFIyOzVizszN	NF\lOGNUSU6JRWK=
NCI-H28	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInjdlhKSzVyPUeuNVY1ODVizszN	MknhV2FPT0WU
MN-60	M1iyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ruXWlEPTB;Nz6yPFA5QSEQvF2=	MXjTRW5ITVJ?
RMG-I	MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPSc3hKSzVyPUeuN\|kzQTZizszN	MXHTRW5ITVJ?
COLO-800	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT3[XpKSzVyPUeuOFE1PDZizszN	NGHDOYVUSU6JRWK=
DB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[1OWtKSzVyPUeuOlExODVizszN	MmPvV2FPT0WU
Ca-Ski	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTdwNkSyOVkh\|ryP	MleyV2FPT0WU
HEL	M{XFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPyTWM2OD15LkexNlA{KM7:TR?=	NGjnc\|VUSU6JRWK=
NH-12	NH3vdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnGdXR[UUN3ME23MlczQDB6IN88US=>	M4HBfXNCVkeHUh?=
LB373-MEL-D	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LqUmlEPTB;Nz63Olc4OSEQvF2=	M4fnV3NCVkeHUh?=
SW900	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTdwOEKxNlEh\|ryP	NH;3XolUSU6JRWK=
JVM-3	NIDnWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LJe2lEPTB;Nz64PVU6QSEQvF2=	MmL3V2FPT0WU
OAW-28	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTdwOUS1O\|gh\|ryP	MWrTRW5ITVJ?
KURAMOCHI	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LG[mlEPTB;Nz65OFgyOSEQvF2=	NXPjdWJ7W0GQR1XS
BE-13	NGnkNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjJUZJvUUN3ME23Mlk5OTF{IN88US=>	NGjzNZpUSU6JRWK=
VMRC-RCZ	M4nXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHYTWM2OD16LkCxOlk4KM7:TR?=	M4TzOXNCVkeHUh?=
NCI-H727	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRThwMUC0NkDPxE1?	M4\sd3NCVkeHUh?=
SW1710	M1jufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPkcGs6UUN3ME24MlE5PTF3IN88US=>	NETmW\|dUSU6JRWK=
D-502MG	M1KxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HES2lEPTB;OD6yPVI5OiEQvF2=	NWizcZREW0GQR1XS
NCI-H1993	M2jFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LzOWlEPTB;OD6zN\|Y{OSEQvF2=	Mlm3V2FPT0WU
SCC-4	M33Tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRThwNESwOVkh\|ryP	NULPTlFzW0GQR1XS
HAL-01	NX7MZotmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVn6e4V{UUN3ME24MlUyQTFizszN	M3fvc3NCVkeHUh?=
GT3TKB	NGT4RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUX4SpRCUUN3ME24MlY4QTZ2IN88US=>	NFvTUHJUSU6JRWK=
SK-OV-3	NUHGdGpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPSblFKSzVyPUiuO\|E{OjlizszN	MUnTRW5ITVJ?
COLO-829	NWm3PVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXCTWM2OD16LkiwPVc3KM7:TR?=	NVHlVZFmW0GQR1XS
OCI-AML2	NYDESVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXIVWs2UUN3ME24Mlk2PDhzIN88US=>	NFvkSGJUSU6JRWK=
OS-RC-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXQNohKSzVyPUmuNFIyQSEQvF2=	NXPSVWg3W0GQR1XS
BFTC-909	NXLrW2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3qe\|ZKSzVyPUmuNFY4QTlizszN	MVjTRW5ITVJ?
EW-11	NXTTcGQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7KTWM2OD17LkG3OlU{KM7:TR?=	NH7mWZBUSU6JRWK=
HCE-4	M2\Femdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml65TWM2OD17LkKxOVU5KM7:TR?=	M3fpTHNCVkeHUh?=
BALL-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\ZTWM2OD17LkKxPVA4KM7:TR?=	NUDHdFkyW0GQR1XS
SF539	M3O4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDW[IFKSzVyPUmuNlM2PjJizszN	MlnSV2FPT0WU
CAMA-1	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe3WmltUUN3ME25MlI5OTJ6IN88US=>	MmThV2FPT0WU
C32	NX;xdmtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzVZ5U4UUN3ME25MlM{ODZ2IN88US=>	NVLoT5ByW0GQR1XS
NCI-H1703	M4DFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGT2bnNKSzVyPUmuN\|Q{PzVizszN	MYnTRW5ITVJ?
NCI-H1650	M4jBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTlwNkC5OFYh\|ryP	NEWxcGJUSU6JRWK=
NCI-H1563	NV;aT29JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3rTWM2OD17Lke2NFMyKM7:TR?=	MWrTRW5ITVJ?
CAL-85-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHkXGNKSzVyPUmuPFc{QDNizszN	MW\TRW5ITVJ?
UM-UC-3	M2XaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn1UYJDUUN3ME25Mlk2ODNizszN	M{XudHNCVkeHUh?=
BxPC-3	NFq3foZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTFyLkC5O\|Ih\|ryP	NVfFUJV4W0GQR1XS
MHH-PREB-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nReGlEPTB;MUCuNVk6QSEQvF2=	MnHsV2FPT0WU
DEL	NHLqT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2K4ZWlEPTB;MUCuN\|k1PiEQvF2=	MXHTRW5ITVJ?
HuCCT1	NWHy[oRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\lTWM2OD1zMD62NFM{KM7:TR?=	NHfh[4pUSU6JRWK=
OVCAR-4	M3THR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHEOGdlUUN3ME2xNE45QDN3IN88US=>	NFv2UXRUSU6JRWK=
CAL-72	NH3DenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\VTWM2OD1zMD65N\|kyKM7:TR?=	NF7DRldUSU6JRWK=
HCC1954	NEfyN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXFZpBKSzVyPUGxMlA4PTRizszN	MXPTRW5ITVJ?
EFO-21	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFzLkGwOFUh\|ryP	NF7HflVUSU6JRWK=
FTC-133	NHHz[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnK0TWM2OD1zMT6xOFA4KM7:TR?=	M2rKdnNCVkeHUh?=
SK-MEL-24	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmi1TWM2OD1zMT6yN\|Y3KM7:TR?=	MW\TRW5ITVJ?
UACC-62	NVTrfo9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH5WnBKSzVyPUGxMlI{PjhizszN	MXrTRW5ITVJ?
NCI-H650	NVTNSWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFzLkK0NVgh\|ryP	NX\5fGZlW0GQR1XS
ALL-PO	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17Dc2lEPTB;MUGuNlUyOiEQvF2=	MoewV2FPT0WU
T84	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHYRlF4UUN3ME2xNU4{QTB5IN88US=>	MUHTRW5ITVJ?
IST-MEL1	NFqyRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILDPGVKSzVyPUGxMlQ2PTlizszN	MYDTRW5ITVJ?
SW626	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfYcJRSUUN3ME2xNU42PzV3IN88US=>	M37vVnNCVkeHUh?=
RPMI-2650	NVjQRnV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXYTndXUUN3ME2xNU42QDh3IN88US=>	NXTKWHF{W0GQR1XS
MC-IXC	NVj2TmQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPCWJRKSzVyPUGxMlY4OjhizszN	NFTXN4JUSU6JRWK=
HOP-62	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHWTWM2OD1zMT62O\|Y1KM7:TR?=	MVXTRW5ITVJ?
NOS-1	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXRPW1KSzVyPUGxMlcyODlizszN	NWXxcpk1W0GQR1XS
SW1573	NUW3enIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHK3bZNKSzVyPUGxMlczQTVizszN	MYPTRW5ITVJ?
WM-115	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1f0OmlEPTB;MUGuO\|U5QCEQvF2=	NGXxR3VUSU6JRWK=
HuO9	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr0TWM2OD1zMT64O\|c1KM7:TR?=	NUDDcHptW0GQR1XS
YAPC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfZTWM2OD1zMT65NlU6KM7:TR?=	NI\DbmFUSU6JRWK=
MDA-MB-453	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13pb2lEPTB;MUGuPVUyPSEQvF2=	NHnYU\|ZUSU6JRWK=
NCI-H596	NWHscHRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHPSVNKSzVyPUGyMlA{PjlizszN	M3;OWnNCVkeHUh?=
A172	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofHTWM2OD1zMj6wO\|k5KM7:TR?=	MlT4V2FPT0WU
RS4-11	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofSTWM2OD1zMj6xO\|I2KM7:TR?=	MnzsV2FPT0WU
HCC1937	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTF{Lke1OlQh\|ryP	NYXTeW1yW0GQR1XS
SW837	NVzESmNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHwTWM2OD1zMj65NFI5KM7:TR?=	MVXTRW5ITVJ?
NMC-G1	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jCNWlEPTB;MUKuPVI{PCEQvF2=	MnnDV2FPT0WU
PFSK-1	M321SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIf0ZplKSzVyPUGzMlA3KM7:TR?=	NWjaZmEzW0GQR1XS
DBTRG-05MG	NE\kRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTF\|LkC2N\|Ih\|ryP	MXvTRW5ITVJ?
SK-UT-1	NHzBcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTF\|LkGwPFMh\|ryP	NH\CN5VUSU6JRWK=
OVCAR-5	NFHJdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTF\|LkG1PVMh\|ryP	NF;MR4VUSU6JRWK=
8505C	M3nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PQfGlEPTB;MUOuNlA3PyEQvF2=	Mk\ZV2FPT0WU
SK-MEL-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTF\|LkexN\|Uh\|ryP	M3H1WXNCVkeHUh?=
LK-2	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jYS2lEPTB;MUOuO\|Y{QSEQvF2=	Mk[yV2FPT0WU
OE33	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF\|Lke4OkDPxE1?	M4DIUHNCVkeHUh?=
Ramos-2G6-4C10	NIf2[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITPcZVKSzVyPUG0MlAzODJizszN	MVXTRW5ITVJ?
EW-13	NHXZV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX0PWp3UUN3ME2xOE4xOzV{IN88US=>	NUX3NnFJW0GQR1XS
NCI-H1793	NUPxfFF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37TfGlEPTB;MUSuNlA5PyEQvF2=	MUHTRW5ITVJ?
BHT-101	M2eyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPxTWM2OD1zND6yOFEh\|ryP	NH\ifHBUSU6JRWK=
RKO	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLmeIloUUN3ME2xOE42ODd3IN88US=>	M4HFTXNCVkeHUh?=
NEC8	NX;COnhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zjSGlEPTB;MUSuOVQ4OiEQvF2=	MYjTRW5ITVJ?
PANC-10-05	M17CRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTF2Lk[yOFch\|ryP	M3LSVHNCVkeHUh?=
NCI-H2030	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zFb2lEPTB;MUSuOlQ1QCEQvF2=	NUXZeJBPW0GQR1XS
C2BBe1	NWX2dZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPqWI8yUUN3ME2xOE44PjRizszN	MlziV2FPT0WU
EM-2	NIrTdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv3TWM2OD1zND64OVc3KM7:TR?=	M{m5WnNCVkeHUh?=
HCC1395	NUXVenRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrxTWM2OD1zND65N\|M5KM7:TR?=	NV7aN4VYW0GQR1XS
A2058	NX7DSpBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEWzUWZKSzVyPUG1MlA1ODlizszN	MnjHV2FPT0WU
SW1463	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mle2TWM2OD1zNT6wOFg2KM7:TR?=	NVLBRVA5W0GQR1XS
J82	NEfIeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXJXIJrUUN3ME2xOU4xPTdizszN	NUX1enE{W0GQR1XS
CAL-120	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljNTWM2OD1zNT6xOFQ4KM7:TR?=	MnS5V2FPT0WU
COLO-824	M{DwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTF3LkG1O\|kh\|ryP	MoPxV2FPT0WU
LNCaP-Clone-FGC	NUPDbJNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPNNZRsUUN3ME2xOU41OjR6IN88US=>	M3j2NnNCVkeHUh?=
CP66-MEL	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfNR3ZLUUN3ME2xOU41Pjh6IN88US=>	MkLlV2FPT0WU
OC-314	M37mcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nVUmlEPTB;MUWuOFcyPCEQvF2=	NVzRbFBTW0GQR1XS
OVCAR-8	NV3YNI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTF3Lki4OlEh\|ryP	M3L4UHNCVkeHUh?=
MFE-280	M4HYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO4c4RKSzVyPUG2MlA1QDhizszN	NVu4eWFpW0GQR1XS
MHH-NB-11	MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTF4LkC4N\|kh\|ryP	MU\TRW5ITVJ?
SW1990	NUXKdIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13WN2lEPTB;MU[uNVc2PSEQvF2=	MoPBV2FPT0WU
U-266	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF4LkKyPVkh\|ryP	NIX0ZYhUSU6JRWK=
MFM-223	NWHRTWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTF4LkO5OlUh\|ryP	NFH0ZmFUSU6JRWK=
L-363	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nST2lEPTB;MU[uOFU4PyEQvF2=	NWH0bm5ZW0GQR1XS
MCF7	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37k[WlEPTB;MU[uOFczOyEQvF2=	NIPifm1USU6JRWK=
SK-MEL-3	M4TOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjmd5kyUUN3ME2xOk41Pzh5IN88US=>	NFf2XHhUSU6JRWK=
HH	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[5VpZjUUN3ME2xOk42OTZ{IN88US=>	NHfHU4FUSU6JRWK=
no-10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTF4Lk[zOFMh\|ryP	MVjTRW5ITVJ?
HuP-T3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLnTWM2OD1zNj62OVc3KM7:TR?=	NF33RXNUSU6JRWK=
QIMR-WIL	NFXicmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGxUJd1UUN3ME2xOk44OTB3IN88US=>	MlmwV2FPT0WU
NCI-H1092	M{XTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF4LkizNVYh\|ryP	NUDCPYY3W0GQR1XS
MZ2-MEL	M4P5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;uXpVKSzVyPUG2Mlg1ODNizszN	MmW5V2FPT0WU
ES3	M1zLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLtUWxGUUN3ME2xOk46OTN2IN88US=>	M4SxR3NCVkeHUh?=
COLO-684	M2XQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlq4TWM2OD1zNj65OFc4KM7:TR?=	MnPlV2FPT0WU
NCI-H661	NH3OSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PzW2lEPTB;MU[uPVY6PCEQvF2=	MnPUV2FPT0WU
CP50-MEL-B	NYrzXldqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojETWM2OD1zNz6wN\|Q{KM7:TR?=	MV3TRW5ITVJ?
NCI-H2405	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;aXGlEPTB;MUeuNVk4PCEQvF2=	MWDTRW5ITVJ?
U-2-OS	NW\Rdmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HNNWlEPTB;MUeuOVMxPyEQvF2=	MX3TRW5ITVJ?
RERF-LC-MS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jMRmlEPTB;MUeuOVUxQCEQvF2=	NVfWVmh{W0GQR1XS
NCI-H2342	M3PJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HSfmlEPTB;MUeuOVU4KM7:TR?=	M{\SSXNCVkeHUh?=
ES8	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\UTnlKSzVyPUG3MlYxQDdizszN	NVTv[YJLW0GQR1XS
MOLT-16	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXJdm9KSzVyPUG3Mlg6OzRizszN	MoftV2FPT0WU
RH-18	NXPId2pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3lTWM2OD1zOD6wNFM2KM7:TR?=	NHq5SXJUSU6JRWK=
D-283MED	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvHZoluUUN3ME2xPE4xODh6IN88US=>	NX;Xb49UW0GQR1XS
RCC10RGB	NETqOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\3W\|lKSzVyPUG4MlA2PTlizszN	NGHwZlNUSU6JRWK=
NCI-H1437	M4jaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHTTWM2OD1zOD6xOlQyKM7:TR?=	NFP0dY1USU6JRWK=
SW982	NE\Zd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrXdFFPUUN3ME2xPE4zPjdzIN88US=>	MXzTRW5ITVJ?
IST-MES1	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDkTWM2OD1zOD60OFI5KM7:TR?=	NE\ZfmdUSU6JRWK=
A704	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\0N2lEPTB;MUiuOFc2OyEQvF2=	NGjYWWlUSU6JRWK=
ESS-1	M3HYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV70ZnlYUUN3ME2xPE42OjB3IN88US=>	MmjRV2FPT0WU
SCH	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;KTWM2OD1zOD62OFU3KM7:TR?=	M{jCWnNCVkeHUh?=
COLO-320-HSR	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33WSWlEPTB;MUiuO\|Q3KM7:TR?=	M1j2PXNCVkeHUh?=
Mo-T	NYPuZ4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2i2RWlEPTB;MUiuPFIxPCEQvF2=	NGTXXGdUSU6JRWK=
Saos-2	NYLybnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXLTWM2OD1zOT6xNVYzKM7:TR?=	NIPQPW9USU6JRWK=
SW684	NIDVfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnN[VlZUUN3ME2xPU4yOzJ4IN88US=>	MoHWV2FPT0WU
KMOE-2	M3PUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTF7LkKyOFIh\|ryP	M33pR3NCVkeHUh?=
MMAC-SF	NXnCdVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fh[mlEPTB;MUmuNlYxPyEQvF2=	NGfiVI1USU6JRWK=
JAR	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\3TWM2OD1zOT6yPVkh\|ryP	MXLTRW5ITVJ?
SK-MEL-28	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvSNXN7UUN3ME2xPU4{OzZ\|IN88US=>	NI\DeG5USU6JRWK=
KNS-81-FD	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHoTWM2OD1zOT61OFY5KM7:TR?=	M3LqU3NCVkeHUh?=
ES7	NGTsdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLVWYVSUUN3ME2xPU43Ojl{IN88US=>	NIfzUJlUSU6JRWK=
AsPC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF7Lk[0O\|Eh\|ryP	M2H6TnNCVkeHUh?=
NCI-H1155	NULoZpRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HUbGlEPTB;MUmuO\|I{QCEQvF2=	MVPTRW5ITVJ?
KYSE-510	M1;vVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTF7Lki3OFgh\|ryP	MWTTRW5ITVJ?
ES1	M1vjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\ZfmlEPTB;MUmuPVIyOyEQvF2=	MX7TRW5ITVJ?
PC-3	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTF7Lkm2NFQh\|ryP	MnjUV2FPT0WU
GCT	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDRUYpZUUN3ME2yNE4{ODJ4IN88US=>	NYq5S3p1W0GQR1XS
KARPAS-299	NX\oO4lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTJyLkO0NlIh\|ryP	NH[yb\|FUSU6JRWK=
DOHH-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTJyLkW0OlMh\|ryP	NYjFV5FLW0GQR1XS
COLO-741	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DmOWlEPTB;MkCuOlYh\|ryP	M1r4PHNCVkeHUh?=
NCI-H1395	NInTcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj5[XlKSzVyPUKwMlY3QTdizszN	Mk\lV2FPT0WU
HCC1187	NHvhWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LY[WlEPTB;MkCuOlc{PCEQvF2=	Mn36V2FPT0WU
Becker	M4HkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJyLkeyNFEh\|ryP	MoPnV2FPT0WU
LU-134-A	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjYboZKSzVyPUKxMlExOjZizszN	NWHrbmFlW0GQR1XS
MKN45	NInod\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:yTm5CUUN3ME2yNU4yPTVzIN88US=>	NXfPNZFUW0GQR1XS
LC-2-ad	NGLmfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPjTWM2OD1{MT6yO\|I6KM7:TR?=	NIS5RVFUSU6JRWK=
EW-24	M4PzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYmyOo5MUUN3ME2yNU4{QTR3IN88US=>	Mn\1V2FPT0WU
SK-N-AS	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHrWmdKSzVyPUKxMlgzPzZizszN	MUPTRW5ITVJ?
NCI-H2052	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7vPYpKSzVyPUKxMlg6PjNizszN	NWPweItwW0GQR1XS
A4-Fuk	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Xrb2lEPTB;MkKuNVQyQSEQvF2=	NVnMXml[W0GQR1XS
NB10	M{W0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXlTWM2OD1{Mj6yN\|cyKM7:TR?=	MljpV2FPT0WU
CHP-212	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTJ{LkOyNlIh\|ryP	M1XnZ3NCVkeHUh?=
KM12	NUHWc2M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJ{LkO1OkDPxE1?	MYjTRW5ITVJ?
JEG-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTJ{LkO3PEDPxE1?	MWDTRW5ITVJ?
LN-405	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;jfVhKSzVyPUKyMlU6OTNizszN	M2jzN3NCVkeHUh?=
HCT-15	NIjrOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTqTWM2OD1{Mj63OFQyKM7:TR?=	MkP0V2FPT0WU
MLMA	M3:5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHf0dZhKSzVyPUKyMlc1PyEQvF2=	MV7TRW5ITVJ?
GI-1	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJ{Lke2OVgh\|ryP	NWPlOpJ1W0GQR1XS
RT-112	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTJ{Lki2NVYh\|ryP	MX7TRW5ITVJ?
MPP-89	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjj[3pSUUN3ME2yNk45PjZzIN88US=>	NGPzOmZUSU6JRWK=
A3-KAW	NX3hbI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PpUGlEPTB;MkOuNVAxOyEQvF2=	NFjGWYFUSU6JRWK=
KALS-1	NGPCbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTJ\|LkG0NVQh\|ryP	MljhV2FPT0WU
SF126	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvYTWM2OD1{Mz62PVI1KM7:TR?=	MnnLV2FPT0WU
SiHa	M3jWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXm[3dKSzVyPUKzMlk{OjdizszN	Mlv2V2FPT0WU
MDA-MB-415	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTJ\|Lkm0PVkh\|ryP	NF7SflRUSU6JRWK=
Daoy	MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Gb2E{UUN3ME2yOE4yOjZizszN	MUjTRW5ITVJ?
COR-L23	NI\FOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm[1TWM2OD1{ND6xO\|Y4KM7:TR?=	MoLhV2FPT0WU
KG-1	NYGxfYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TWSGlEPTB;MkSuNVkzQCEQvF2=	M1L5cHNCVkeHUh?=
L-428	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofTTWM2OD1{ND61O\|kyKM7:TR?=	NHHMO4RUSU6JRWK=
NCI-H520	NVnT[3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHVTWM2OD1{ND64PFYyKM7:TR?=	NWCzSJl1W0GQR1XS
COLO-792	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTJ3LkK3N\|Ih\|ryP	MkfYV2FPT0WU
NB12	M3jnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XOfWlEPTB;MkWuNlk1PyEQvF2=	M2nWZXNCVkeHUh?=
GAK	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjscXlDUUN3ME2yOU4zQTZ\|IN88US=>	M1K1bXNCVkeHUh?=
SW780	NGnmXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPGTWM2OD1{NT6zNlY1KM7:TR?=	NFO0W4hUSU6JRWK=
GB-1	NH\wfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHrSGZKSzVyPUK1MlQxPjlizszN	M4PL[XNCVkeHUh?=
P12-ICHIKAWA	NIfScZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTJ3LkS3PFUh\|ryP	NHzOT\|dUSU6JRWK=
NCI-H1651	M2PYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDxW5lsUUN3ME2yOU42QTdizszN	MnrMV2FPT0WU
KE-37	NVyxWXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH23UZpKSzVyPUK1Mlc{OTVizszN	MX;TRW5ITVJ?
CCRF-CEM	NGT1WpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTJ3Lkm2O{DPxE1?	Mn\0V2FPT0WU
SF295	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXiSVhNUUN3ME2yOk4xPDJ3IN88US=>	MmrtV2FPT0WU
G-361	NFq1U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTJ4LkGwNlch\|ryP	NHLC[ohUSU6JRWK=
HOP-92	M{XReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDiTWM2OD1{Nj6xNlI3KM7:TR?=	M3rZWnNCVkeHUh?=
UMC-11	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnqzTWM2OD1{Nj60OVE1KM7:TR?=	M13FUXNCVkeHUh?=
IST-SL1	NXHRcZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJ4Lk[1PVEh\|ryP	NVeySYZLW0GQR1XS
TE-11	M{DWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLMbIhsUUN3ME2yOk44PzV{IN88US=>	MWrTRW5ITVJ?
NCI-H1304	NIO4U\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzYeXBKSzVyPUK2MlkyODhizszN	Mmj5V2FPT0WU
SJSA-1	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fFWGlEPTB;MkeuNFE4PiEQvF2=	NHTJc5pUSU6JRWK=
BCPAP	NEWyb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoW4TWM2OD1{Nz6xN\|ch\|ryP	NYLtcHhVW0GQR1XS
HTC-C3	Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi0RnBpUUN3ME2yO{4zPTZzIN88US=>	NXnYbZpTW0GQR1XS
EW-16	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3vTWM2OD1{Nz6yPVQ4KM7:TR?=	NF\5OVBUSU6JRWK=
HT-144	M1XUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrFTWM2OD1{Nz60NFMzKM7:TR?=	NVzuWpZ{W0GQR1XS
MHH-ES-1	M1Ls[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j1[GlEPTB;MkeuOFQ1PyEQvF2=	Mlj3V2FPT0WU
T98G	NXnXVpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrKUWtKSzVyPUK3MlU5PDZizszN	MnTHV2FPT0WU
RPMI-8866	NHXuNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJ5Lke1OlIh\|ryP	NFjkb29USU6JRWK=
BEN	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zlUGlEPTB;MkeuPFUyPyEQvF2=	Mm\iV2FPT0WU
MDA-MB-231	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3tTWM2OD1{OD6yO\|k2KM7:TR?=	NIi4c5ZUSU6JRWK=
HuH-7	NIXufYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTJ6LkSwNlgh\|ryP	NI\MXpdUSU6JRWK=
SK-N-FI	NFPF[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfQNHo2UUN3ME2yPE41OzNizszN	MUjTRW5ITVJ?
AN3-CA	M1y1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELUSmJKSzVyPUK4MlQ{QTVizszN	MmThV2FPT0WU
EGI-1	M3nOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjsPW9iUUN3ME2yPE42QTJ6IN88US=>	M1;y[3NCVkeHUh?=
697	NEXrWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnERWZKSzVyPUK4MlY{OzFizszN	NEP0UIpUSU6JRWK=
TCCSUP	NX:1U2xbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTGUmI6UUN3ME2yPE43PDF6IN88US=>	NFuyUoFUSU6JRWK=
GR-ST	M3;OVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LVXGlEPTB;MkiuOlY6PiEQvF2=	NG\YOnlUSU6JRWK=
SK-N-DZ	NGfFellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fsUmlEPTB;MkiuOlg5PSEQvF2=	NGXSbIhUSU6JRWK=
MIA-PaCa-2	NWjVbpVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvX[2JKSzVyPUK4Mlc6PTlizszN	M13QfHNCVkeHUh?=
IGR-1	NXq0VnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTJ6Lki4O\|Qh\|ryP	MYnTRW5ITVJ?
BFTC-905	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDYUphwUUN3ME2yPU4zPzB3IN88US=>	M2DkSXNCVkeHUh?=
NCI-H1581	NUe1O49IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTiTWM2OD1{OT6zNVQ2KM7:TR?=	MnjUV2FPT0WU
RD	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPuTWM2OD1{OT61NlM{KM7:TR?=	NEnhcXVUSU6JRWK=
SF268	M{e2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXaRlVWUUN3ME2yPU42QTNzIN88US=>	NGX2fohUSU6JRWK=
SHP-77	NWq0XpdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M170WGlEPTB;MkmuOlE5OiEQvF2=	NGryOJZUSU6JRWK=
D-566MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPmTWM2OD1{OT65N\|k{KM7:TR?=	Mln6V2FPT0WU
TGBC1TKB	NGO2Z\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\xfnpKSzVyPUOwMlEzOzhizszN	NHnsVoJUSU6JRWK=
MEL-HO	NHH1dYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HwbmlEPTB;M{CuNVQzOyEQvF2=	NI\JOnVUSU6JRWK=
SJRH30	M2TMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P5cWlEPTB;M{CuNlExQCEQvF2=	NHj0OZFUSU6JRWK=
D-336MG	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUixNFNiUUN3ME2zNE4zQDl{IN88US=>	NV\0RoFTW0GQR1XS
C3A	NH21Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfUfnk2UUN3ME2zNE4zQTJ5IN88US=>	Mlf5V2FPT0WU
Calu-6	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnvTZBKSzVyPUOwMlI6PjNizszN	NETvc4pUSU6JRWK=
MZ1-PC	M4Xu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vBfWlEPTB;M{CuN\|k{KM7:TR?=	MWHTRW5ITVJ?
KYSE-70	M4q2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTNyLkWxNVQh\|ryP	MUHTRW5ITVJ?
CAPAN-1	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTNyLkWxPFEh\|ryP	NEfXWJhUSU6JRWK=
DK-MG	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7GTWM2OD1\|MD61OFU3KM7:TR?=	NVi4VFFNW0GQR1XS
SK-HEP-1	NX7QSYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXvTWM2OD1\|MD62N\|I3KM7:TR?=	MmfNV2FPT0WU
MS-1	NHu3dWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzYTWM2OD1\|MD64PFg6KM7:TR?=	NYfzeWEzW0GQR1XS
GI-ME-N	NFP6U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\wTWM2OD1\|MT6wOVcyKM7:TR?=	M3Hl[nNCVkeHUh?=
NCI-H510A	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTNzLkSwNFYh\|ryP	MX\TRW5ITVJ?
NB17	NUDLbopJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIniR3ZKSzVyPUOxMlUyQDVizszN	NY\DNYR5W0GQR1XS
639-V	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LadWlEPTB;M{GuOVI1OyEQvF2=	M3PnWHNCVkeHUh?=
CAL-51	M{P0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDwbIFKSzVyPUOxMlU3PjdizszN	NWfYdZFpW0GQR1XS
HGC-27	NWHLdG1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEni[ZRKSzVyPUOxMlU5PzNizszN	MUXTRW5ITVJ?
GOTO	Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LwXmlEPTB;M{GuPFUxPiEQvF2=	Mn3qV2FPT0WU
ChaGo-K-1	NYjwZ\|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\WTWM2OD1\|Mj6wNFch\|ryP	MWfTRW5ITVJ?
RO82-W-1	M{HvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;ycWlEPTB;M{KuNVYxPCEQvF2=	MlrpV2FPT0WU
SH-4	NVHiWVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHDTWM2OD1\|Mj6xPFU5KM7:TR?=	NELxPGZUSU6JRWK=
A204	M1iwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTN{LkWwOlkh\|ryP	NXLaN\|I4W0GQR1XS
DMS-273	NHziNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\qRllJUUN3ME2zNk42OzJ{IN88US=>	MlTrV2FPT0WU
KGN	MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\uZ2lEPTB;M{KuOlM{KM7:TR?=	MVHTRW5ITVJ?
SK-MEL-2	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn3UZpKSzVyPUOyMlY2OjdizszN	MWPTRW5ITVJ?
NCI-H2228	M2nkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjOPZZKSzVyPUOyMlY3ODJizszN	MVHTRW5ITVJ?
MKN28	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjBU4tnUUN3ME2zNk44QDN6IN88US=>	MkizV2FPT0WU
H-EMC-SS	M1;iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH5eZlKSzVyPUOyMlk3PzhizszN	NFiybIhUSU6JRWK=
ATN-1	M4DpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrC[HBXUUN3ME2zN{4yPDF4IN88US=>	M13DN3NCVkeHUh?=
D-263MG	NHzYZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXKTWEzUUN3ME2zN{45Ozd6IN88US=>	NH:yNm5USU6JRWK=
LU-135	NVXhbYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHThfpNKSzVyPUOzMlg5OjlizszN	NWf0bpY5W0GQR1XS
C8166	MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;kTWM2OD1\|Mz64PFU1KM7:TR?=	NFvQfYFUSU6JRWK=
T-24	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPnTWM2OD1\|ND6wNlA2KM7:TR?=	M365e3NCVkeHUh?=
Mewo	NYXCeGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HqfGlEPTB;M{SuNVM1QSEQvF2=	M37uZXNCVkeHUh?=
22RV1	M1zTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTN2LkG3OVQh\|ryP	M4XjWHNCVkeHUh?=
KM-H2	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnC[pliUUN3ME2zOE4yPzd7IN88US=>	MWDTRW5ITVJ?
NCI-H2122	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TDTWlEPTB;M{SuN\|Q4OSEQvF2=	MlLVV2FPT0WU
ABC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPjRYRKSzVyPUO0MlM3QTNizszN	MVPTRW5ITVJ?
NCI-H1355	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT0TWM2OD1\|ND6zPFg6KM7:TR?=	MX;TRW5ITVJ?
NOMO-1	M{HYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi1UW1SUUN3ME2zOE42PzB\|IN88US=>	NUTxSYZHW0GQR1XS
MZ7-mel	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHiTWM2OD1\|ND62OFg4KM7:TR?=	NGO1ZmVUSU6JRWK=
NCI-H810	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr4TWM2OD1\|ND63Nlc5KM7:TR?=	M3zQOnNCVkeHUh?=
D-392MG	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPycFdPUUN3ME2zOU4xPTZ3IN88US=>	MW\TRW5ITVJ?
LB771-HNC	MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nMeWlEPTB;M{WuNVY2QCEQvF2=	Ml;IV2FPT0WU
COLO-679	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPITWM2OD1\|NT6zPFgh\|ryP	MVzTRW5ITVJ?
SK-PN-DW	NVrlb5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPI[IkyUUN3ME2zOU41OzZ7IN88US=>	M2rqdXNCVkeHUh?=
VA-ES-BJ	NWPmR2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTEOWNKSzVyPUO1MlQ3PDlizszN	NITT[VVUSU6JRWK=
KNS-42	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTN3LkW4NlYh\|ryP	NE\FNGhUSU6JRWK=
RVH-421	NF\oSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTN3Lke2OFUh\|ryP	NXjKOJFxW0GQR1XS
P30-OHK	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrQUnJ3UUN3ME2zOU45PzV{IN88US=>	M{TMU3NCVkeHUh?=
G-402	NELsSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDlRYtKSzVyPUO1Mlk5PjdizszN	MUTTRW5ITVJ?
S-117	NW\rSJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXpZ3FXUUN3ME2zOk4{ODB6IN88US=>	M1HEWnNCVkeHUh?=
RXF393	NIDhPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfSWnZvUUN3ME2zOk4{Pzh3IN88US=>	MnewV2FPT0WU
LCLC-103H	NYXwemVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTN4Lke4NFMh\|ryP	NYfQTpdNW0GQR1XS
U-118-MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHJenVsUUN3ME2zOk45QDR5IN88US=>	MoPyV2FPT0WU
8-MG-BA	NWj5cG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHWzOWlKSzVyPUO2Mlk1QDNizszN	MW\TRW5ITVJ?
MFH-ino	NUfjUVhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHFTWM2OD1\|Nz6zN\|cyKM7:TR?=	NEK3SHNUSU6JRWK=
NCI-H23	M1XhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzmTWM2OD1\|Nz60NVk3KM7:TR?=	M3\zUXNCVkeHUh?=
NCI-H446	NV[zbZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnmyTWM2OD1\|Nz60PFYzKM7:TR?=	NIPBfFFUSU6JRWK=
LU-99A	M3PvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HZWWlEPTB;M{euOVc{OSEQvF2=	NVHpTWh{W0GQR1XS
KP-N-YN	NI[2R\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTN5Lk[xPVUh\|ryP	NUnRXYx1W0GQR1XS
SCC-9	NInkWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN5Lke4N\|gh\|ryP	MlPBV2FPT0WU
EFM-19	NV76NY46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1O2VGlEPTB;M{euO\|k3PyEQvF2=	NInXNlBUSU6JRWK=
A427	NX3hbWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDvTYhWUUN3ME2zO{46OTB5IN88US=>	NEflOFJUSU6JRWK=
LB831-BLC	NGPYNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLHTWM2OD1\|OD62NFM6KM7:TR?=	NHX2PZBUSU6JRWK=
HOS	M4T4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTN7Lk[yO\|Mh\|ryP	MYTTRW5ITVJ?
LAN-6	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnWxTWM2OD12MD6wNVEzKM7:TR?=	M3vX[HNCVkeHUh?=
U251	NWj6eIYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzXSFJKSzVyPUSwMlQxPTRizszN	M2\zOHNCVkeHUh?=
SNU-387	NX7ucI1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;MZWV{UUN3ME20NE41PTV\|IN88US=>	MkTxV2FPT0WU
DMS-79	NHvhRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXe1WWNnUUN3ME20NE42QDh7IN88US=>	NWfndm9zW0GQR1XS
SK-LU-1	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1u4O2lEPTB;NECuOlU3QCEQvF2=	MXPTRW5ITVJ?
HT	NITxe\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MormTWM2OD12MD62OlM6KM7:TR?=	NVXxS3BtW0GQR1XS
KP-N-YS	NHLYTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrDTWM2OD12MD62O\|Y5KM7:TR?=	MoezV2FPT0WU
DMS-114	NWDNNpFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTRyLkizO\|Qh\|ryP	MlLzV2FPT0WU
HUTU-80	NEj2[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTRzLkC1Olkh\|ryP	NXj3dWZFW0GQR1XS
ONS-76	NVTmdHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zvdGlEPTB;NEGuOFcxQSEQvF2=	Mkf6V2FPT0WU
A673	M3LUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnKblFOUUN3ME20NU42OTV5IN88US=>	MkDPV2FPT0WU
HPAF-II	M3\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrlXFZKSzVyPUSxMlY4ODlizszN	NF3SOGdUSU6JRWK=
UACC-257	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDrdldpUUN3ME20NU44OzZ7IN88US=>	MWXTRW5ITVJ?
EW-22	NV:ySW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXz[ItKUUN3ME20NU45Pjl5IN88US=>	M4O4XHNCVkeHUh?=
NCI-H1755	NVPBNZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmKwTWM2OD12MT64O\|I2KM7:TR?=	M12zRnNCVkeHUh?=
KYSE-150	NV\KV3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGG4OVVKSzVyPUSyMlE4QDJizszN	MYnTRW5ITVJ?
CGTH-W-1	M3\0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTFToZKSzVyPUSyMlQ6PTVizszN	NIrqb45USU6JRWK=
NB13	M4\rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTR{Lk[yNVch\|ryP	M3q0c3NCVkeHUh?=
SW872	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD5NXhKSzVyPUSyMlY{OzFizszN	M2KyTHNCVkeHUh?=
KP-4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTR{Lki4N\|Ih\|ryP	M1OxV3NCVkeHUh?=
HCC38	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LT[2lEPTB;NEKuPVYyQCEQvF2=	M2rXbXNCVkeHUh?=
BB49-HNC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrPemRKSzVyPUSzMlI{PTZizszN	NY\De\|JLW0GQR1XS
CAL-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\RPHcxUUN3ME20N{41ODJ6IN88US=>	MkG1V2FPT0WU
NCI-H2029	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnoTWM2OD12Mz61OVgyKM7:TR?=	MkHnV2FPT0WU
M14	NF64cIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XadmlEPTB;NESuNVM{OiEQvF2=	Ml;1V2FPT0WU
COLO-680N	NVT1d4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnL6TWM2OD12ND6zN\|kh\|ryP	MVHTRW5ITVJ?
Hs-578-T	M3Lpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLNTWM2OD12NT6wNlk1KM7:TR?=	MUfTRW5ITVJ?
MSTO-211H	NIDUW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTJTWM2OD12NT65OFgzKM7:TR?=	NGDRNJpUSU6JRWK=
EW-1	M3:5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTR3Lkm2PFkh\|ryP	NFHIUXFUSU6JRWK=
SW948	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTR4LkS0OlIh\|ryP	NXyxdotqW0GQR1XS
NCI-H460	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\2TWM2OD12Nj61NlMh\|ryP	M3HuW3NCVkeHUh?=
CAS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTkTWM2OD12Nj63O\|AyKM7:TR?=	NHLHOJlUSU6JRWK=
TGBC11TKB	NEftOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTR5LkG3O\|ch\|ryP	NHH4VHFUSU6JRWK=
HD-MY-Z	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTR6Lke4OkDPxE1?	NFTNcG9USU6JRWK=
NCI-H226	NIDMUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPTcmRKSzVyPUS5Mlc4QDVizszN	MUjTRW5ITVJ?
PA-1	Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDqfJZKSzVyPUS5Mlg{OzVizszN	NVjrRVdZW0GQR1XS
LB2518-MEL	NH;yfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTR7Lki3NlMh\|ryP	M4PXb3NCVkeHUh?=
A101D	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYH0fnhGUUN3ME20PU46PDJ3IN88US=>	M4npdnNCVkeHUh?=
NCI-H2087	NXTXcIN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvpTWM2OD12OT65OlgzKM7:TR?=	NU\CRoFIW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Water	Insoluble
	Ethanol	''15 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	850140-72-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04497584	Not yet recruiting	Drug: Afatinib + Prednisone	Advanced Squamous Non Small Cell Lung Cancer	University of Texas Southwestern Medical Center	September 1 2020	Phase 2
NCT04413201	Not yet recruiting	Drug: Afatinib\|Drug: Osimertinib	Non-squamous NSCLC	Michael Hopp\|Boehringer Ingelheim\|Johannes Gutenberg University Mainz	June 30 2020	Phase 4
NCT04206787	Recruiting	Drug: Afatinib	Non-squamous Non-Small Cell Lung Cancer	Boehringer Ingelheim	May 20 2020	--
NCT04158947	Recruiting	Drug: Afatinib\|Drug: T-DM1	HER2-positive Breast Cancer\|Brain Metastases	xuexin he\|Second Affiliated Hospital School of Medicine Zhejiang University	May 10 2020	Phase 2
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)